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ARTICLE
A structurally distinct TGF-β mimic from an
intestinal helminth parasite potently induces
regulatory T cells
Chris J.C. Johnston1,2, Danielle J. Smyth1,3, Ravindra B. Kodali4, Madeleine P.J. White3, Yvonne Harcus1,
Kara J. Filbey1,8, James P. Hewitson 1,9, Cynthia S. Hinck4, Alasdair Ivens1, Andrea M. Kemter1,
Anna O. Kildemoes 1,10, Thierry Le Bihan1, Dinesh C. Soares 5, Stephen M. Anderton5, Thomas Brenn 6,
Stephen J. Wigmore2, Hannah V. Woodcock7, Rachel C. Chambers7, Andrew P. Hinck4, Henry J. McSorley1,5
& Rick M. Maizels3
Helminth parasites defy immune exclusion through sophisticated evasion mechanisms,
including activation of host immunosuppressive regulatory T (Treg) cells. The mouse parasite
Heligmosomoides polygyrus can expand the host Treg population by secreting products that
activate TGF-β signalling, but the identity of the active molecule is unknown. Here we identify
an H. polygyrus TGF-β mimic (Hp-TGM) that replicates the biological and functional prop-
erties of TGF-β, including binding to mammalian TGF-β receptors and inducing mouse and
human Foxp3+ Treg cells. Hp-TGM has no homology with mammalian TGF-β or other
members of the TGF-β family, but is a member of the complement control protein super-
family. Thus, our data indicate that through convergent evolution, the parasite has acquired a
protein with cytokine-like function that is able to exploit an endogenous pathway of immu-
noregulation in the host.
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Parasitic helminths are able to establish a state of immunehypo-responsiveness or tolerance in their host to attenuateboth host immunity and reactivity to third-party speciﬁ-
cities, such as allergens and autoantigens1–3. A wide range of
molecular and cellular mechanisms of parasite immune sup-
pression have been described, but a prominent feature of many
helminth infections is expansion of the regulatory T (Treg) cell
population, an immune subset that controls immunity in infec-
tion, allergy, and autoimmunity4–6. Activation of Treg cells is
particularly marked in mice infected with the gastrointestinal
nematode Heligmosomoides polygyrus, with Treg cells controlling
both susceptibility to infection and propensity to allergic reac-
tivity7–10. In particular, antibody-mediated depletion of Treg cells
promotes resistance to infection in genetically susceptible mice,
and Treg population expansion (with IL-2:anti-IL-2 complex)
renders genetically resistant mice susceptible10.
In the mature peripheral immune system, induction of Treg
cells to exogenous antigen speciﬁcities, for example from the
microbiota or innocuous environmental substances, is promoted
by the cytokine TGF-β11–14. Mice deﬁcient in either the TGF-β1
ligand or TGF-β receptors have few inducible Treg cells and
succumb to disseminated inﬂammatory disease in the weeks
following birth15. TGF-β is a member of a highly diversiﬁed
signaling family, which includes many essential developmental
and morphogenetic proteins, and indeed mice lacking the TGF-
β2 and TGF-β3 isoforms develop lethal congenital deformities16,
17. TGF-β family members have developmental functions in
invertebrates, including helminths such as Caenorhabditis
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Fig. 1 Identiﬁcation of Hp-TGM. a Fractionation of HES by gel ﬁltration FPLC. 1 mg of HES was separated on a Superdex 200 10/300 GL column and 1 ml
fractions collected for assay with MFB-F11 reporter cells; responses were calibrated with recombinant human TGF-β1. b as a, fractionation by ion exchange
FPLC on a Mono QTM 5/50 G column. c Abundance of a candidate protein, Hp_I03161_IG00349_L1408, calculated by the exponentially modiﬁed Protein
Abundance Index (emPAI) in each fraction, compared to the activation of TGFβ-responsive cells by the same fraction. d TGF-β bioassay screen of four
candidate recombinant clones designated A–D; clone B corresponds to candidate Hp_I03161_IG00349_L1408 shown in panel c. Supernatants of cells
transfected with clones A–D were assayed in duplicate, and mean values± SEM are shown. Two-tailed t tests found Clone B to be signiﬁcantly (p< 0.05)
higher than all others. e Alignment of ﬁve similar domains within Hp-TGM encompassing the entire amino acid sequence apart from the predicted signal
peptide (aa 1–18), with conserved cysteine (white on red) and other residues indicated, together with a Complement Control Protein (CCP) module from
the nematode Ascaris suum (domain 12 of ASU_08405, aa 954–1018), and an archetypal CCP domain, human Factor H module 1 (X07523, aa 20–83).
Other conserved residues are shown in red and potential N-glycosylation sites outlined in green. Amino acid positions for each domain of Hp-TGM are
indicated on the left. Note the presence of a 15-aa insertion near the N-terminal of each domain of Hp-TGM which is not typical of the CCP family. Positions
of disulﬁde bonds in Factor H are shown below the alignment by linked cysteine residues CI – CIV. f Exon-intron structure of Hp-TGM in the H. polygyrus
genome; domains are colored corresponding to symbols in panel e; positions of cysteine residues indicated in black circles
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elegans18 and H. polygyrus19, indicating that the immunological
function of mammalian TGF-β emerged at a relatively recent
point in evolution20.
We previously reported that H. polygyrus releases a soluble
secreted product which activates the mammalian TGFβ receptor
pathway to induce expression of the Treg-speciﬁc transcription
factor, Foxp3, in naive peripheral T cells9; however, the identity of
the active protein among more than 370 different products
released by the parasite21, 22 is unclear.
Here we identify and characterize a secreted functionally active
404-aa protein, which although highly cysteine-rich, has no
sequence similarity to mammalian TGF-β and does not contain a
cystine knot, like all other members of the highly diversiﬁed TGF-
β family. However, the newly identiﬁed product is a fully func-
tional mimic of the mammalian cytokine, and is able, in a parallel
fashion, to bind the TGF-β receptors and activate signalling; as a
result the mimic we call H. polygyrus TGF-β mimic (Hp-TGM)
potently induces expression of Foxp3 in mouse and human
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Fig. 2 Binding of Hp-TGM to the TGF-β Receptors. aMFB-F11 TGF-β-responsive bioassay for activity following 24 h of culture at 37 °C, comparing Hp-TGM
to hTGF-β1 and the complex HES mixture by protein concentration. MFB-F11 cells are transfected with a Smad-responsive plasmid construct in which TGF-β
binding leads, through Smad phosphorylation and nuclear translocation, to expression of alkaline phosphatase, which is measured following the addition of
p-nitrophenyl phosphate. Data shown are representative of > 3 independent experiments, and represent mean± SEM from duplicate wells.
b–e Surface plasmon resonance analysis of Hp-TGM and hTGF-β3 binding to hTGF-β receptors. Streptavidin-coated biosensor chips were loaded with
biotinylated Hp-TGM or hTGF-β3 and two-fold dilutions of the ectodomain of hTβRII (from 13 µM downwards) b, c and of the ectodomain of hTβRI (from
4 µM downwards) d, e were passed over the Hp-TGM or hTGF-β3 surface, respectively. Data shown are from one of two similar experiments. f, g Surface
plasmon resonance analysis of Hp-TGM and hTGF-β3 binding to TβRI in the presence of near-saturating TβRII (2 μM), showing independent binding by Hp-
TGM to both receptors, but binding of hTGF-β3 to TβRI dependent on the presence of TβRII
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T cells. This ﬁnding indicates convergent evolution of immuno-
suppressive mediators by host and parasite, generating a distinct
TGF-β mimic that may have therapeutic value in inhibiting
inﬂammatory disorders in humans.
Results
Identiﬁcation of a TGF-β mimic from H. polygyrus. To identify
TGF-β-like activity, we screened H. polygyrus excretory-secretory
products (HES) for their ability to activate the MFB-F11 ﬁbroblast
cell line in which an alkaline phosphatase reporter is activated by
the Smad pathway upon receptor ligation23. HES proteins were
independently fractionated by gel ﬁltration and anion exchange
Fast Protein Liquid Chromatography (FPLC), and each fraction
assayed for activity on the reporter cell line (Fig. 1a, b). All frac-
tions were then subject to mass spectrometric analysis for
matching to a transcriptomic sequence database as previously
described21. Eighteen proteins were identiﬁed for which abun-
dance (measured by exponential mass protein abundance index,
emPAI) was highest in the active fractions from both gel ﬁltration
and anion exchange (Supplementary Table 1); we selected 4
candidates to clone and express for which the abundance proﬁle
most closely matched biological activity in each fraction, as in the
example shown in Fig. 1c, and in Supplementary Fig. 1.
For each candidate, mammalian codon-optimised sequences
were synthesized and cloned into the plasmid vector pSecTag2a
for transfection of human embryonic kidney HEK293 cells and
expression as secreted recombinant proteins with hexa-histidine
C-terminal tags. The supernatants of transfected cell cultures
were collected and applied directly to the MFB-F11 assay. One
transfectant (Hp_I03161_IG00349_L1408, the candidate shown
in Fig. 1c), showed a high level of stimulatory activity, far
exceeding that of total HES; this clone is depicted as clone B in
Fig. 1d. From this clone, recombinant 49-kDa protein was
expressed and puriﬁed by nickel chelating chromatography
through afﬁnity for the hexa-histidine tag. Following conﬁrma-
tion that the puriﬁed recombinant protein displayed TGF-β-like
activity (see below), it was named H. polygyrus TGF-β Mimic
(Hp-TGM).
The amino acid sequence of active Hp-TGM comprises 422
residues, of which the ﬁrst 18 are predicted to form a classical
signal peptide (Supplementary Fig. 2), with the remainder
forming a mature 404-aa protein containing 22 cysteine residues
(yellow on black) and 5 potential N-glycosylation sites (green).
The protein has no sequence similarity to the TGF-β family in
which the mature active moiety is a disulﬁde-linked homodimer
of two ~ 110-aa C-terminal polypeptides with 6–9 cysteine
residues. However, the mature protein of Hp-TGM contains 5
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Fig. 3 Hp-TGM signals through the TGF-β pathway. a Activity shown from MFB-F11 bioassay after 24 h of culture at 37 °C with hTGF-β1 or Hp-TGM
incubated with anti-TGF-β monoclonal antibody or MOPC31C IgG control. Data shown are representative of two independent experiments, and represent
mean± SEM from duplicate wells; analysis by multiple t tests shows antibody signiﬁcantly reduces effect of TGF-β (P< 0.0001), but has no signiﬁcant
effect on TGM. b, c Abolition of signaling by inhibitors of the TGF-β receptor kinases. Activity shown from MFB-F11 bioassay after 24 h of culture of TGF-β
and Hp-TGM at 37 °C with: b the TβRI inhibitor, SB431542 or DMSO control and c the TβRII inhibitor, ITD-1 (10 µM). Data shown are representative of≥ 2
independent experiments, and represent mean± SEM from duplicate wells. Analysis by multiple t tests shows that effects of both mediators are
signiﬁcantly reduced by SB431542 (p< 0.0001) and ITD-1 (P< 0.001). d Western blots (Smad2 and phospho-Smad2): cell lysates from C57BL/
6 splenocytes following culture at 37 °C for 18 h. Culture conditions in duplicate: media (DMEM+ 2.5% FCS), media supplementted with 20 ng/ml hTGF-
β1 and media supplemented with 20 ng/ml Hp-TGM. Position of a 49-kDa marker protein detected by negative staining is marked on each blot. e Phospho-
Flow analysis with anti-phospho-Smad2/3 on murine CD4+ T cells stimulated for 16 h with 20 ng/ml of Hp-TGM or hTGF-β1, before permeabilization and
staining with speciﬁc antibody. A representative individual histogram is displayed
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Fig. 4 Hp-TGM induces T cell Foxp3 expression even in proinﬂammatory conditions. a, b CD4+CD25–GFP–CD62Lhi murine naive T cells were stimulated
with plate-bound anti-CD3/CD28 for 4 days in culture with 100 U/ml IL-2 and variable concentrations of Hp-TGM or hTGF-β1, before ﬂow cytometric
analysis of CD4, CD25 and Foxp3 expression; 2 technical replicates per concentration; representative of 4 independent experiments;. a: percentage of
CD25+Foxp3+ cells among total CD4+ cells; b, Mean ﬂuorescence intensity (MFI) of Foxp3 among Foxp3+ cells. Gating strategy is shown in Supplementary
Fig. 6. c–e Foxp3 induction in the same conditions as a, in the presence of SB431542 inhibitor c or pan-vertebrate anti-TGF-β d, e; 2 technical replicates per
concentration; representative of 3 independent experiments. Analysis by multiple t tests showed no signiﬁcant difference in responses to TGM when anti-
TGF-β was present, but signicant effects (p< 0.01) on responses to all concentrations of TGF-β. f, gMagnetically sorted murine CD4+ T cells were cultured
for 5 days with Th17-promoting ligands (100 ng/ml IL-6, 5 ng/ml IL-23, 10 ug anti-IFN-γ), together with the indicated concentrations of Hp-TGM or TGF-β,
then stimulated with PMA/ionomycin in the presence of Brefeldin A for 4.5 h before staining for intracellular Foxp3 and IL-17. Data are mean± SEM of
triplicate replicates from 1 of 2 independent experiments; data were analysed by multiple t tests which showed no signiﬁcant difference at any
concentration of TGF-β v TGM for percentage IL-17+, and p< 0.001 and p< 0.01, respectively for 10 and 50 ng/ml TGM v TGF-β for percentage Foxp3+.
Gating strategy is shown in Supplementary Fig. 6. h, i Murine CD4+ T cells were cultured as above with but with Th9-promoting ligands (40 ng/ml IL-4,
20 ng/ml IL-2), and assayed as above after 4 days of culture by staining for intracellular Foxp3 and IL-9. Data are mean± SEM of three replicates from 1 of
2 independent experiments; data were analysed by multiple t tests which showed p< 0.05 for 1 ng/ml TGF-β v TGM for percentage IL-9+, and p< 0.001
for 10, 50, and 100 ng/ml TGM v TGF-β for percentage Foxp3+. Gating strategy is shown in Supplementary Fig. 6
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homologous but non-identical ~ 80-aa domains each with distant
similarity to the Complement Control Protein (CCP, or Sushi)
family as marked by the positions of 4 cysteine residues and
conserved tyrosine, glycine and tryptophan residues (Fig. 1e).
Moreover, the mature protein is encoded in an 11-exon gene in
the parasite genome, corresponding to the signal peptide (Exon 1)
and 5 pairs of exons whose boundaries exactly match those of the
CCP domains (Fig. 1f).
Hp-TGM ligates TGF-β receptors. We next tested the ability of
puriﬁed recombinant Hp-TGM protein (Supplementary Fig. 3) to
activate MFB-F11 cells in vitro, in comparison to human TGF-β1
(hTGF-β1) and HES; all three induced reporter cell production of
alkaline phosphatase in a dose-dependent manner (Fig. 2a).
Notably, the primary Hp-TGM product proved to be active
without the need for proteolytic processing to a mature form (as
is required for mammalian TGF-β). The response of MFB-F11
cells to increasing concentrations of Hp-TGM reached a max-
imum signal signiﬁcantly greater than attained by even the
highest concentrations of hTGF-β1 (OD405 at 100 ng/ml, Hp-
TGM= 2.46± 0.16 and hTGF-β1= 1.48± 0.02, p= 0.02, multi-
ple t test).
The MFB-F11 response to HES also exceeded the highest level
of the TGF-β-induced signal, but required more than three log-
fold higher concentrations to achieve the same signal as Hp-TGM
(Fig. 2a). This indicated that Hp-TGM represents < 0.1% of the
total protein present in HES, consistent with its low abundance
ranking, from the mass spectrometric analysis even in the
fractions that show peak TGF-β activity (Supplementary Table 1).
To ascertain whether Hp-TGM directly binds to TGF-β
receptors (TβR), and to evaluate its binding afﬁnity, recombinant
protein was evaluated by surface plasmon resonance (SPR) with a
sensor chip loaded with either Hp-TGM or human hTGF-β3; as
shown in Fig. 2b–e, upon injection of hTβRII), this receptor
bound Hp-TGM with lower afﬁnity than hTGF-β3 (Fig. 2b, c),
with a dissociation constant of 2.96 µM compared to 0.294 µM for
hTGF-β3 (Supplementary Table 2). Remarkably, Hp-TGM bound
directly to hTβRI with high afﬁnity (Fig. 2d and Supplementary
Table 2), in distinction to hTGF-β3, which alone binds hTβRI
weakly (Fig. 2e)24–26. In contrast, binding of hTβRII had little to
no effect on the binding of hTβRI to Hp-TGM (Fig. 2f), but it did
strongly potentiate the binding of hTβRI to hTGF-β3 (Fig. 2g), as
previously reported24–26. Hp-TGM shows no binding afﬁnity for
TβRIII (also known as betaglycan), which is recognised by
mammalian TGF-βs (Supplementary Fig. 4A).
We then established if Hp-TGM signaling could be inhibited by
antibody to mammalian TGF-β, to exclude the possibility that the
parasite protein interacts with or activates the host cytokine in
tissue culture medium. MFB-F11 cells were ﬁrst co-cultured with
Hp-TGM or hTGF-β1 and 100 μg/ml pan-vertebrate anti-TGF-β
antibody (clone 1D11) or MOPC murine IgG control. Anti-TGF-
β antibody considerably inhibited the MFB-F11 signal generated
from hTGF-β1, but had no impact on Hp-TGM (Fig. 3a).
Consistent with these ﬁndings, 1D11 antibody bound only hTGF-
β3 and not Hp-TGM by SPR (Supplementary Fig. 4B), while
polyclonal rat anti-Hp-TGM IgG bound only Hp-TGM and not
hTGF-β3 (Supplementary Fig. 4C).
To establish if Hp-TGM transduces canonical signalling
following TGF-β receptor ligation, the MFB-F11 cells were
stimulated in the presence or absence of inhibitors of receptor
kinase activity. We ﬁrst tested the kinase inhibitor SB431542
which blocks phosphorylation by TβRI, as well as other TGF-β
family type I receptors Alk5 and Alk727. SB431542 has previously
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Fig. 5 Hp-TGM induces Foxp3 expression in human T cells. a–c Human peripheral blood mononuclear cells were separated from red blood cells over a
Ficoll gradient and CD4+ T cells isolated by MACS positive selection. Isolated cells were cultured at 37 °C for 96 h with a 1:1 ratio of CD3/CD28
Dynabeads® and variable concentrations of hTGF-β1 or Hp-TGM. Induction of Tregs from human peripheral blood monuclear cells. Data are means and
SEM from two technical replicates per concentration and representative of 2 independent experiments, analysed by unpaired t test and corrected for
multiple comparisons; *p< 0.05. Gating strategy is shown in Supplementary Fig. 6. a Representative ﬂow cytometry plots (CD4+ population shown) of
MACS-puriﬁed CD4+ positive selected PBMCs stimulated with Hp-TGM, hTGF-β or IL-2 respectively; b Percentage of CD25+Foxp3+ cells among total CD4
+ cells; c MFI of Foxp3 among Foxp3+ cells
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Fig. 6 Hp-TGM drives immune regulation in vitro and in vivo. a Mouse Foxp3+ Treg cells are suppressive in vitro. CD4+CD25+GFP+ cells, generated as
Fig. 4a were isolated by FACS and co-cultured with CD4+CD25–GFP– responder cells from Foxp3-GFP mice together with, irradiated APCs and anti-CD3
for 5 days. Proliferation was assessed by thymidine incorporation, and percentage suppression calculated; data are means± SEM from 3 replicates per
concentration and represent two independent experiments. b Hp-TGM prolongs survival of fully allogeneic full-thickness BALB/c to C57BL/6 skin grafts.
Kaplan–Meier curve of graft survival: allograft only (n= 6), allograft + HES or Hp-TGM following implantation of intraperitoneal minipumps, n= 6) and
syngeneic controls, n= 3. Mantel-Cox comparison of allograft vs. allograft + Hp-TGM survival curves: p= 0.0136. c, d Histological analyses of graft sites
7 days following transplantation; c, representative images of tissues sections, scale bars= 100 µm; d, scoring of inﬂammation on 3 sections per graft
performed in a blinded fashion: syngeneic control (n= 7), allograft + control protein (n= 14), allograft + HES (n= 13), allograft + TGM (n= 12); data shown
combine two independent experiments, with mean± SEM shown. HES vs untreated allogeneic control p= 0.0493; Hp-TGM v untreated control p=
0.0397, by unpaired t test. e, f Treg and Th17 CD4+ T cell populations 21 days after transplantation, in e draining lymph node Foxp3+ (syngeneic controls
(n= 3), allograft + control protein (n= 6), allograft + TGM minipump (n= 6); two-tailed, unpaired t test: p= 0.0042) and f spleen RORγt+ (syngeneic
controls (n= 3), allograft + control protein (n= 7), allograft + TGM minipump (n= 6); two-tailed, unpaired t test: p= 0.0112). Gating strategy is shown in
Supplementary Fig. 6. g, h Fibrogenesis in human lung ﬁbroblasts exposed to TGFβ1 or Hp-TGM, assayed by immunoﬂuoresence for collagen deposition (g,
see Supplementary Fig. 8A for quantitative summary) and smooth muscle actin (h, presented as quantitative summary, see Supplementary Fig. 8B for
ﬂuorescence micrographs). Human collagen I stained with AF488-conjugated scondary antibody (green) and counterstained with DAPI (blue). Scale bars
= 200 µm. Data are means± SEM from 1 of 3 replicate experiments, with 4 technical replicates per group
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been found to block the TGF-β-like activity of unfractionated
HES, and to render mice more resistant to H. polygyrus
infection9. Both Hp-TGM and hTGF-β1 signals were completely
ablated in the presence of SB431542 (Fig. 3b). We repeated this
assay with “Inducer of Type II TGF-β Receptor Degradation-1”
(ITD-1)28, which also completely ablated the MFB-F11 signal
generated by Hp-TGM and hTGF-β1 (Fig. 3c), indicating that
both ligands directly signal through the same combination of type
I and II receptors on mammalian cells.
Further evidence that Hp-TGM can signal through the TGF-β
pathway was found when stimulating splenocytes from C57BL/6
mice. Following overnight incubation with saturating concentra-
tions of each ligand, cells were collected and assayed for Smad2/3
phosphorylation by Western blotting and ﬂow cytometry. As
shown in Fig. 3d, e, Hp-TGM induces phosphorylation of Smad2/
3 phosphorylation at least as effectively as TGF-β). In contrast, no
activation of either the Akt pathway (Supplementary Fig. 5A) or
the p38 pathway (Supplementary Fig. 5B) was evident with either
host or parasite ligand.
Treg cell induction by Hp-TGM. H. polygyrus and HES have
previously been shown to induce Foxp3+ Treg cells in vitro and
in vivo8, 9, 29. We therefore next ascertained if Hp-TGM could
induce Foxp3+ Treg cell differentiation in vitro and if the evi-
dence of potent intracellular signalling would be reﬂected in the
level of Foxp3 expression within the induced Treg population.
CD4+CD25–GFP–CD62Lhi cells were isolated from Foxp3-GFP
reporter mice30 by MACS and FACS sorting, then cultured for 96
h in Treg polarising conditions with hTGF-β1 or Hp-TGM. Hp-
TGM was found to effectively induce Foxp3+ Treg cell differ-
entiation: at the highest concentration tested (38.1 ng/ml, 0.78
nM) Hp-TGM induced Treg cell conversion in 90.65% (±3.55%)
of all CD4+ cells, compared to 79.65% (±2.55%) induced by a
similar molar concentration (10 ng/ml, or 0.39 nM homodimeric
hTGF-β1, effectively 0.78 nM monomer concentration) of the
human cytokine (Fig. 4a). Further, the mean ﬂuorescence inten-
sity of Foxp3 expression induced by high concentrations of Hp-
TGM was found to be greater than that of the equivalent con-
centration of hTGF-β1 (Fig. 4b). Hp-TGM-mediated induction of
Foxp3 was completely abolished by the TGF-βRI kinase inhibitor
SB431542 (Fig. 4c), but not by pan-vertebrate anti-TGF-β anti-
body (Fig. 4d), while the presence of either reagent blocked the
effect of the mammalian ligand (Fig. 4c, e).
In the presence of other cytokines such as IL-6 and IL-4, TGF-
β is known to promote in vitro differentiation of effector T cell
subsets designated as Th1731 and Th932 respectively. We
therefore evaluated whether Hp-TGM exhibits corresponding
activity on puriﬁed murine CD4 + T cells. In the presence of IL-6,
both TGF-β and Hp-TGM induced similar levels of Th17
development as measured by intracellular staining of IL-17,
particularly at lower ligand concentrations (Fig. 4f). However,
under the same conditions, Hp-TGM was able to drive a
signiﬁcant expansion of Foxp3+ Treg cells, which at higher
ligand concentrations even outnumbered the Th17 population
(Fig. 4g) and few of which co-expressed IL-17 (data not shown).
In the case of Th9-favouring conditions including IL-4, TGF-β
and Hp-TGM elicited broadly similar outcomes in terms of IL-9+
T cells (Fig. 4h), although again a signiﬁcant induction of Foxp3+
Treg cells was also observed particularly in the presence of Hp-
TGM (Fig. 4i).
As Hp-TGM was found by SPR to bind to the human TβRs, we
then tested whether it could drive expression of Foxp3 in human
CD4+ T cells puriﬁed from peripheral blood cultured with anti-
CD3/CD28 Dynabeads and variable concentrations of Hp-TGM
or hTGF-β1 for 96 h before assessment of CD25 and Foxp3
expression. As shown in Fig. 5a, b the proportion of CD4+CD25
+Foxp3+ Treg cells increased with Hp-TGM in a concentration-
dependent fashion, to a maximum of 84% (±2.5%). The
proportion of Treg cells within all CD4+ cells was similar for
Hp-TGM and hTGF-β1 at most concentrations; however, at
higher concentrations, the mean ﬂuorescence intensity (MFI) of
Foxp3 expression was signiﬁcantly greater in Treg cells exposed
to Hp-TGM compared to hTGF-β1 (Fig. 5c).
To further establish if Hp-TGM can induce immune
suppressive function in naïve T cells, murine Treg cells generated
from sorted CD4+CD25–GFP–CD62Lhi cells incubated with
hTGF-β1 and Hp-TGM were added to CD4+CD25−GFP
−CD62Lhi responder cells together with soluble anti-CD3 and
irradiated APC. Assessment of responder cell proliferation by
thymidine incorporation demonstrated that Hp-TGM-generated
Treg are functionally suppressive in vitro with suppressive
capacity equivalent to TGF-β-generated Treg cells (Fig. 6a).
Anti-inﬂammatory effects of Hp-TGM. To test the efﬁcacy of
Hp-TGM in an in vivo model of immunopathology, we examined
its effects in a model of allograft rejection, as helminth parasites
and their products have been previously described to prolong the
life of tissue transplants33. We chose the fully allogeneic skin
transplant model, from BALB/c donor mice to C57BL/6 reci-
pients, a system in which median rejection occurs in ~9 days,
mediated by Th1 and Th17 inﬂammatory responses. This
represents a robust and intense allogeneic reaction34–36 but one
which is known to be down-modulated by adoptive transfer of
Treg populations37. Hp-TGM or HES were administered to mice
through osmotic mini-pumps inserted intraperitoneally to con-
tinuously release parasite products in a manner akin to live
infection. Both Hp-TGM and HES conferred a signiﬁcant pro-
traction of allograft life, with median survival extended by
~ 5 days relative to untreated controls (Fig. 6b); it is worth noting
that such extension reﬂects a very effective immune modulation
comparable with, for example, the recent use of mesenchymal
stem cells in this model38.
In parallel experiments, inﬂammation at the graft site was
assessed 7 days post-transplant in animals treated with HES or
Hp-TGM, in comparison to controls. As shown in Fig. 6c, both
treatments reduced histological features of rejection such as
dermal inﬂammation and epidermal degeneration. Sections were
evaluated blindly using the Zdichavsky scoring system39, reveal-
ing signiﬁcantly attenuated rejection reactions in recipients of
both HES and Hp-TGM (Fig. 6d).
In allograft recipients exposed to Hp-TGM, a signiﬁcant
increase in Foxp3+ expression was observed in the allograft
draining lymph node (Fig. 6e) and spleen (Supplementary
Fig. 7A) at day 21. Moreover, the expression of T cell RORγt,
indicative of Th17 expansion induced by the allograft, was
reduced in recipients of Hp-TGM to the level observed in
syngeneic graft recipients (Fig. 6f), as was expansion of Tbet+
Th1 cells (Supplementary Fig. 7B). In separate experiments, when
lymphoid tissues were sampled 7 days following allografting,
similar reductions of inﬂammatory cell phenotypes were
observed, including diminished T-bet expression among total
CD4+ T cells (Supplementary Fig. 7C).
Mammalian TGF-β is a multi-faceted molecule with effects
beyond the regulatory T cell circuit, which can contraindicate its
therapeutic use as an immunosuppressant or anti-inﬂammatory
agent. Within the T cell compartment, TGF-β is associated with
Th17 differentiation when IL-6 is present in vitro31, 40, or when
TGF-β is over-expressed in Freund’s complete adjuvant-
immunized mice40; the suppression of RORγt expression by
Hp-TGM in allogeneic skin graft recipients suggests that the
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parasite ligand does not potentiate Th17 responses in vivo, while
our in vitro assays indicate that Hp-TGM can still induce
signiﬁcant regulatory T cell development even in a nominally
pro-inﬂammatory environment (Fig. 4f–i). A second potential
therapeutic limitation of TGF-β arises from its ability to induce
ﬁbrosis41, promote myoﬁbroblast differentiation and excessive
deposition of extracellular matrix. Importantly, we found that
Hp-TGM is signiﬁcantly less ﬁbrogenic than mammalian TGF-β
in terms of promoting ﬁbroblast collagen I deposition (Fig. 6g,
Supplementary Fig. 8A) and alpha-smooth muscle actin induc-
tion (Fig. 6h, Supplementary Fig. 8B) in human lung ﬁbroblasts.
Finally, a caveat of applying xenogeneic proteins in a therapeutic
context in vivo is the potential generation of neutralizing
antibodies in the recipient; this may militate against protocols
requiring repeated administration of Hp-TGM in vivo, but would
not exclude ex vivo applications, for example conversion of
patients’ T cells in vitro into the regulatory phenotype prior to
return to the autologous individual.
Discussion
Helminth parasites are now well-known to exploit the immu-
noregulatory power of the TGF-β pathway, driving the produc-
tion of this cytokine by host cells, and promoting longer-term
establishment of the parasite in mammalian tissues. Many
pathogens, particularly viruses, imitate host cytokines, or even
express cytokine genes originally captured from the genome of
their host42. However, no previous example has been reported of
a completely unrelated structural product elaborated by parasites
that so closely mimics the activity of a crucial host cytokine.
Furthermore, the imitation of TGF-β is itself striking, as this
mediator is the single most immune-suppressive and pro-
tolerogenic product of the host immune system involved in a
suite of critical immunoregulatory pathways43. The ability of
TGF-β to induce and expand suppressive Treg cells is arguably
the most prominent immunological function of TGF-β12, 44, 45,
while Treg cells have been shown to be essential for the survival of
several helminth parasites in vivo4, 5 including H. polygyrus10.
As metazoa, helminth organisms also encode endogenous
members of the TGF-β ligand and receptor families, which in
some settings can interact with cognate partners of vertebrate
origin46–50. Further, we had reported that immunomodulatory
Treg cells were induced by H. polygyrus secreted products acting
through the TGF-β pathway9. We now identify the molecular
agent responsible, and ﬁnd that rather than belonging to the
classical TGF-β family, the parasite molecule represents an
unexpected and novel structure. This ﬁnding emphasizes the
remarkable immunomodulatory strategy of H. polygyrus which
has convergently evolved, from the scaffold of the CCP family, a
unique multi-domain structure able to signal through the TGF-β
pathway and, like TGF-β itself, induce potently suppressive Treg
cells and abate inﬂammation in vivo.
Despite ligating the TGF-β signaling receptors, TβRI and
TβRII, and driving Smad phosphorylation, Hp-TGM is structu-
rally distinct from the TGF-β molecule and evidently binds TβRI
and TβRII sites that are well-separated, and not directly adjacent
to one another as in the TGF-β receptor complex24, 25. Hp-TGM
shares no sequence homology with TGF-β, is almost twice the size
of a TGF-β homodimer (49 kDa vs. 25 kDa), and is not recog-
nised by pan-vertebrate anti-TGF-β antibodies. Furthermore, Hp-
TGM is constitutively active, in contrast to the TGF-β ligands
which are processed from a longer pro-protein to a mature ~ 110-
aa growth factor domain by proteolytic cleavage at a conserved
furin site (RRXR)51.
Hp-TGM is a member of the CCP superfamily deﬁned by a
60–80 aa domain with 4 cysteines and key characteristic residues
including a conserved tryptophan. In most eukaryotic species,
including nematodes, the protein family has expanded and
radiated with extensive diversity of structure and function.
Interestingly, searching the genomes of the human hookworms
Necator americanus52 and Ancylostoma duodenale reveals 12–18
members of this gene superfamily, each with low levels of
sequence similarity to Hp-TGM. It remains to be determined if
one or more of these homologues may share the cytokine-like
activity of Hp-TGM.
A notable ﬁnding has been that Hp-TGM stimulates greater
expression of Foxp3 compared to that achieved with TGF-β in
both murine and human CD4+ T cells. Intensity of Foxp3
expression by Treg cells has previously been shown to directly
correlate with suppressive ability53 while high concentrations of
TGF-β favour Treg over Th17 differentiation54. Further studies
are required to ascertain if Hp-TGM is able to deliver a stronger
signal through the canonical TGF-β receptor cascade, or is per-
haps inured to inhibitory pathways that naturally counteract
signals from the mammalian ligand such as the pseudoreceptor
BAMBI55.
Within the inducible Treg compartment, expression of Foxp3
and consequent regulatory function is in some settings rever-
sible56, 57. We are now studying whether Hp-TGM drives a more
stable and longer-lasting Treg phenotype, and/or one less inﬂu-
enced by inﬂammatory cytokines such as IL-6. If so, then new
therapies such as autologous transfusion following ex vivo
expansion of Treg cells58 may be much enhanced in terms of both
efﬁcacy and safety.
The ability of Hp-TGM to delay allograft rejection, and to
inhibit all three major subsets of effector CD4+ T cells in vivo,
also portends well for a therapeutic application of this new
molecule. Recombinant Hp-TGM offers several advantages
including scalable production, a deﬁnable mechanism of action
and the opportunity for modiﬁcation to reduce immunogenicity
and optimise pharmacokinetic characteristics for pharmacological
use. Furthermore, combinations of Hp-TGM with currently
available immunomodulatory agents may further enrich future
therapeutic strategies in which the directed manipulation of the
different T cell subsets will offer resolution of inﬂammatory
conditions of diverse aetiologies.
Methods
Mice. Inbred female C57BL/6 J OlaHsd, BALB/c OlaHsd, and Foxp3-GFP reporter
mice30 were used for experiments, aged 6–12 weeks old, bred in-house or pur-
chased from Harlan Laboratories, and maintained in individually-ventilated cages.
All animal experiments were performed under UK Home Ofﬁce licence and
approved by the University of Edinburgh and/or University of Glasgow Ethical
Review Board(s). No randomization was used and no animals were excluded from
analysis.
Fractionation of HES and mass spectrometric analysis. Heligmosomoides
polygyrus Excretory Secretory (HES) products were prepared as described else-
where59. HES was separated into 1 ml fractions using an ÄKTApuriﬁerTM (GE
Healthcare) using either the Superdex 200 10/300 GL column (GE Healthcare) for
gel ﬁltration fractionation or the Mono QTM 5/50 GL (GE Healthcare) for anion
exchange fractionation. The protein concentration of fractions was measured by
Pierce BCA Protein assay kit (Thermo Scientiﬁc) with 5 μg of each fraction being
trypsin digested, analysed using an Orbitrap mass spectrometer and then compared
to an in house H. polygyrus transcriptomics database using the Mascot program set
with default parameters (Matrix Science), to generate a Protein Score and a
probability (p) that a match would occur by chance; proteins calculated by the
Mascot program to return a score below 20 or p> 0.05 were not considered. Scripts
written in Python 2.7 were used to analyse the mass spectrometry results.
Recombinant Hp-TGM. Recombinant Hp-TGM was synthesised as a mammalian
codon optimised insert (GeneArt) and cloned into the mammalian expression
vector pSECTag2a (Invitrogen). The construct was transfected into HEK293T cells
using the calcium chloride transfection method (Promega) and recombinant Hp-
TGM was puriﬁed from culture supernatant by Ni-chelating chromatography
(Supplementary Fig. 2).
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Antibodies and inhibitors. The mouse monoclonal pan-isoform speciﬁc TGF-β
IgG antibody, 1D1160, was purchased (BioXCell), as were the inhibitors SB431542
(Tocris Bioscience) and ITD-1 (Tocris Bioscience). The mouse IgG1 myeloma
MOPC 31 C from ATCC (ECACC-90110707) was used as an isotype control.
Smad2/3 antibody (Cell Signaling Technology) and phosphoSmad2 antibody (Cell
Signaling Technology) was used as the primary antibody for Western blots, fol-
lowed by Goat anti rabbit IgG-HRP secondary (BioRad) according to manu-
facturer’s protocols. Recombinant Hp-TGM was detected by Western blot using an
anti penta-His-HRP conjugate (Qiagen). An uncropped image of the Western blot
shown in Fig. 3d is presented in Supplementary Fig. 9.
TGF-β bioassay. The TGF-β bioassay (MFB-F11) developed by Tesseur et al.23
was used with embryonic ﬁbroblasts from TGF-β1–/– mice stably transfected with a
TGF-β-responsive reporter plasmid containing a secreted embryonic alkaline
phosphatase reporter gene (SBE-SEAP). MFB-F11 cells were grown in DMEM with
10% FCS, 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine and
supplemented with 15 μg/ml Hygromycin B (Invitrogen), for 3 days. Cells were
tested and found to be mycoplasma-free. Conﬂuent cells were detached with
trypsin, and resuspended in DMEM with 2.5% FCS, 100 U/ml penicillin, 100 μg/ml
streptomycin and 2 mM L-glutamine at a concentration of 4 × 105 cells/ml. In 50
μl, 4 × 104 cells were added to each well of a 96-well round-bottomed plate. Serial
dilutions of test substances HES (in-house), Hp-TGM (in-house), and recombinant
human TGF-β1 (R&D Systems) were then added to each well in a volume of 50 μl
and incubated for 24 h at 37 °C. Subsequently, 20 μl of supernatant was aspirated
from each well, added to an ELISA plate (NUNC) with 180 μl of reconstituted
Sigma FastTM p-nitrophenyl phosphate substrate and incubated at RT in the dark
for up to 4 h. Plates were read on at 405 nm on an Emax precision microplate
reader (Molecular Devices).
Recombinant proteins for surface plasmon resonance. The human TGF-β type I
and type II receptor extracellular domains, hTβRI and hTβRII, were produced as
insoluble proteins in E. coli and reconstituted, refolded, and puriﬁed to homo-
geneity as previously described61, 62. The rat TGF-β type III receptor extracellular
domain, which is also known as rTβRIII or r-betaglyan, was produced in cultured
HEK293 freestyle cells (Invitrogen) and puriﬁed to homogeneity using metal
afﬁnity chromatography and size exclusion chromatography as described else-
where63. Human TGF-β3 (hTGF-β3), and human TGF-β3 bearing an N-terminal
15 amino acid Avitag64 followed by an EY linker (Avi-hTGF-β3), were produced in
E. coli, reconstituted in urea, refolded, and puriﬁed to homogeneity using ion-
exchange chromatography, as previously described65. The mouse monoclonal pan-
isoform speciﬁc TGF-β IgG antibody, 1D1160, was purchased (BioXCell), whereas
the rat polyclonal anti-Hp-TGM antibody was produced in-house by immunization
with 10 µg protein in alum adjuvant on days 0, 28, and 35, with serum recovered on
day 42.
Biotinylated Avi-hTGF-β3 for surface plasmon resonance (SPR) studies was
generated by complexing Avi-hTGF-β3 with r-betaglycan in 10 mM bicine at pH
8.0 and then biotinylated by incubating with a catalytic amount of bacterially
expressed BirA recombinase, biotin, magnesium, and ATP at 37 °C for 2 h, as
described64. Biotinylated Avi-hTGF-β3 was then bound to a C4 reverse phase
column equilibrated with 94.9% water/5% acetonitrile/0.1% triﬂouroacetic acid and
eluted with a linear acetonitrile gradient. Attachment of a single biotin to each
protein chain was conﬁrmed by measuring the intact mass of the biotinylated,
puriﬁed proteins using electrospray ionization-time of ﬂight mass spectrometry
(Agilent). Hp-TGM was biotinylated using EZ-Link Sulfo-NHS-Biotin (Thermo
Scientiﬁc) according to the manufacturer’s protocol.
SPR. SPR was used to assess the binding of hTβRI, hTβRII, and r-betaglycan) to
Hp-TGM and hTGF-β3. SPR was also used to validate the Hp-TGM and hTGF-β3
surfaces using a rat polyclonal Hp-TGM antibody and mouse monoclonal pan-
isoform speciﬁc TGF-β antibody, 1D1160. A BIAcore 3000 SPR instrument (GE
Lifesciences) was used for studying antibody, betaglycan, and TβRII binding with
streptavidin-coated carboxy methyl dextran (CM5) sensor chips (GE Lifesciences)
with biotinylated Avi-hTGF-β3 or Hp-TGM captured at a surface density of
400–500 resonance units (RU). A BIAcore × 100 instrument (GE Lifesciences) was
used for studying hTβRI binding, either in the absence or presence of 2 μM hTβRII,
with hTGF-β3 and Hp-TGM covalently attached to a carboxymethylated dextran
sensor chip (CM5, GE Lifesciences) by carbodiimide-based amine coupling.
Coupling of hTGF-β3 and Hp-TGM to the sensor chip was performed using an
amine coupling kit (GE Lifesciences) according to manufacturer’s protocol.
SPR binding assays were performed by injecting two-fold serial dilutions of
analytes in HBS-EP buffer (GE Healthcare) at a ﬂow rate of 100 µLmin−1 (Hp-
TGM antibody, 1D11 antibody, r-betaglycan, or hTβRII) or 30 µLmin−1 (hTβRI)
over the hTGF-β3 and Hp-TGM surfaces. hTβRI binding was also investigated in
the same manner, but with 2 mM hTβRII included in both the HBS-EP running
buffer as well as the injected hTβRI samples. All injections were performed at room
temperature and were preceded by a brief injection of 4M guanidine hydrochloride
for 30 s to regenerate the surface. Baseline correction was performed by double
referencing63. Kinetic analyses were performed by global ﬁtting with a simple 1:1
model using the Biaevaluation software (GE Lifesciences).
Cellular immunology assays. Single cell suspensions were made from murine
spleen and lymph node specimens by maceration through 70 μm ﬁlters (BD) into
complete RPMI 1640 (cRPMI) medium containing HEPES (Gibco), supplemented
with 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco),
10% heat-inactivated foetal calf serum (FCS) (Gibco), and 50 nM 2-
mercaptoethanol (Gibco). Contaminating red blood cells were removed by resus-
pending the cells from one spleen in 2 ml of red blood cell lysis buffer (Sigma) and
incubating at RT for 2 min. Cells were then washed with cRPMI and counted on a
haemocytometer by trypan blue exclusion. For human lymphocytes, fresh per-
ipheral blood was obtained by venepuncture of healthy volunteers under a protocol
approved by the University of Edinburgh research ethics committee. Blood was
collected into heparinised tubes (BD) and immediately diluted 1:1 with PBS,
centrifuged over Ficoll-Paque (GE Healthcare) at 400×g for 40 min at RT with no
brake, and PBMCs recovered from the interface before three further washes in
cRPMI at 200 g for 10 min (RT). Finally, cells were counted on a haemocytometer
in preparation for culture.
Flow cytometric analysis and cell sorting. For viability staining, LIVE/DEAD®
ﬁxable blue (Life Technologies) was diluted to 1:1000 in PBS; 200 μl was added to
each sample of cells, which were then incubated in the dark for 20 min at 4 °C
(protected from light) and washed twice in FACS buffer. To prevent non-speciﬁc
antigen binding, cells were incubated with 50 µl of polyclonal IgG (diluted 1:50 in
FACS buffer) for 10 min at 4 °C and then washed twice in FACS buffer. All samples
were acquired on a BD Biosciences LSR II or LSR Fortessa ﬂow cytometer and
analysed using FlowJo software (Tree Star).
The following FACS antibodies were diluted to an appropriate ﬁnal
concentration in FACS buffer (or permeabilisation buffer (eBioscience) for
intracellular antibodies): Anti-CD3-FITC (17A2, Biolegend, 1/200); anti-CD4-
AF700 and –BV650 (RM4-5, Biolegend, 1/200); anti-CD8-PerCP (53–6.7,
Biolegend, 1/200); anti-CD25−APC (PC61-5, eBioscience, 1/200); anti-Foxp3-
ef450, (FJK-16s, eBioscience, 1/50), anti-ROR-gamma(t)-PE (AFKJS-9,
eBioscience, 1/50); anti-Tbet-PerCP-Cyanine (eBio4BIO, eBioscience, 1/50) to a
total volume of 50 μl diluted antibody per 5 × 106 cells. Single stain controls were
individually added to one drop of UltraComp eBeads (eBioscience). Samples were
incubated for 20 min at 4 °C, washed twice in FACS buffer and then resuspended in
200 μl FACS buffer for acquisition of surface marker data directly or further
processed for intracellular staining.
CD4+ T cell enrichment by magnetic sorting. Cells were resuspended in MACS
buffer at a volume of 45 μl per 107 cells, together with 5 μl of microbeads (L3T4,
Miltenyi Biotech), and incubated at 4 °C for 20 min. Cells were then washed three
times in MACS buffer, centrifuging at 200×g for 5 min, and resuspended in MACS
buffer at a volume of 50 μl per 107 cells. CD4+ cells were then isolated by per-
forming a positive selection using an AutoMACS (Miltenyi Biotech) automated
magnetic column as per the manufacturer’s instructions. The positive fraction of
cells was then resuspended in MACS buffer and counted.
Fluorescence-activated cell sorting. CD4+ cells (freshly isolated or from culture)
were enriched by magnetic sorting as above and then incubated with antibodies for
surface markers as described above, but with the omission of a viability stain.
Following staining, cells were resuspended in MACS buffer at a concentration of
5 × 108 cells per ml. Sorting was performed on a BD FACSAria with a gating
strategy of: lymphocytes (by forward and side scatter), single cells and then stained
populations, e.g., CD4+CD25–Foxp3–CD62Lhi. Cells were sorted into 2 ml of FCS
(Gibco) and a sample from each tube was re-acquired on the FACSAria to assess
the purity of each sort.
T cell polarization. To provide conditions for TH9 and Th17 cell polarization,
CD4+ T cells enriched by magnetic sorting were cultured at 1 × 105 per well in ﬂat-
bottomed 96-well plates (Costar) pre-coated with 2 μg/ml αCD3 (eBioscience) and
2 μg/ml or 1 μg/ml αCD28 (eBioscience), for Th9 and Th17 conditions respectively.
Cytokines for Th9 conditions were added in complete medium as follows 40 ng/ml
IL-4, 20 ng/ml IL-2 and for Th17 conditions 100 ng/ml IL-6, 5 ng/ml IL-23 (all
from Miltenyi Biotech) and both polarization cultures contained 10 μg/ml αIFN-γ
(BioXcell) in addition to varying concentrations of hp-TGM or hTGF-β3. Cultures
were left at 37 °C with 5% CO2 and restimulated with 500 ng/ml PMA, 500 ng/ml
ionomycin and 1 µg/ml BFA (Sigma Aldrich) for 4.5 h on day 4 (Th9) or day 5
(Th17) followed by staining for ﬂow cytometry with the FoxP3 transcription factor
buffer kit (eBioscience) as detailed below, as well as for intracellular IL-9 with anti-
IL-9-PE (BioLegend 514104) and for IL-17 with anti-IL-17-PE (bioLegend 506904).
Foxp3+ Treg cell induction. A single-cell suspension was prepared from the spleen
and peripheral lymph nodes of Foxp3-GFP transgenic mice. CD4 + CD25-GFP-
CD62Lhi cells were then isolated by MACS followed by FACS sorting (see previous
sections). Sorted cells were washed twice in complete RPMI and then resuspended
in complete RPMI at a concentration of 5 × 105 cells per ml. CD3/CD28-coated 24
well plates (Costar) were prepared by adding 250 μl per well of CD3 and CD28
(eBioscience), both at 2 μg/ml in PBS, incubating for 2 h at 37 °C and then washing
three times in PBS. In total 5 × 105 cells were then added to each well in 1 ml of
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complete RPMI. Each well was made up to ﬁnal volume of 2 ml complete RPMI,
containing variable concentrations of treatment conditions (e.g., TGF-β) and IL-2
(produced in-house) at a ﬁnal concentration of 100 U/ml. Cells were removed after
96 h for ﬂow cytometric analysis.
Transcription factor staining. For analysis of transcription factors, cells were
resuspended in 400 μl ﬁxation/permeabilisation buffer (eBioscience) and incubated
at 4 °C for between 1 and 18 h. Following incubation, cells were resuspended and
washed twice in 1 ml permeabilisation buffer (eBioscience). In total 50 μl of anti-
body or isotype control (diluted in permeabilisation buffer) was added to each
sample. Cells were resuspended by gentle vortex and incubated at room tem-
perature for 30 min. Finally, cells were washed in 2 ml of FACS buffer and
resuspended in 200 μl FACS buffer for acquisition.
Phosﬂow staining. MACS-puriﬁed CD4 + T cells were cultured in 100 μl in FACs
tubes (BD Bioscience) at a concentration of 2–5 × 106 cells/ml in serum free
DMEM, supplemented with 2 mM L-gluatmine and 100 U/ml Pen/Strep (Gibco),
overnight at 37 °C with 5% CO2. Cells were stimulated by the addition of hp-TGM
(20 ng/ml), hTGF-β3 (20 ng/ml) or DMEM for 30 min or 16 h before ﬁxation.
Samples were ﬁxed and stained using phosﬂow methods recommended by BD
Bioscience. In brief, samples were ﬁxed by the addition of 2 ml pre-warmed 1×
Phosﬂow Lyse/Fix buffer (BD Bioscience) and mixed by inverting, followed by
several washing steps in FACs buffer. The samples were permabilised by the
addition of 1 ml of pre-chilled (0–4 °C) Phosﬂow Perm Buffer III (BD Bioscience)
for 30 min on ice, followed by several washing steps in FACs buffer. Phosﬂow
antibodies and isotype controls were added in 100 μl volume of FACs buffer as per
manufactures instructions (BD Bioscience) and left at room temperature for 1 h in
the dark. The samples were washed and resuspended in FACs buffer followed by
analysis on a BD Celesta ﬂow cytometer (BD Bioscience), using the following
antibodies: anti-pAKT-PE (BD#560378), anti-p38-PE (BD #612585), or pSMAD2/
3- PE (BD#562586).
Treg suppression assays. Tregs induced as above were washed in MACS buffer
and the CD4+CD25+GFP+ Treg population was isolated by FACS sorting.
Responder cells (CD4+CD25–GFP–CD62Lhi) were also isolated from a fresh
Foxp3-GFP transgenic mouse. 104 responder cells were added to each well of a 96
well round-bottomed plate together with 105 irradiated APCs, 2 μg/ml soluble
CD3 stimulation and a variable concentration of Treg. Proliferation was assessed
after 72 h by thymidine incorporation.
Continuous infusion via osmotic minipump. Alzet minipumps (Charles River
UK) of 100 µl capacity were selected according to the duration of infusion required
for individual experiments (model 1007D—7 days; model – 1002–14 days; model
1004–28 days). Minipumps were ﬁlled with the substance for infusion (HES, Hp-
TGM or PBS control) and primed overnight by incubation in PBS at 37 °C.
Under general anaesthesia, abdominal fur was removed by shaving and the skin
was prepared with chlorhexidine solution. The peritoneal cavity was accessed
through an upper midline incision and the minipump was placed in the right
paracolic gutter. Closure was in two layers with 5–0 undyed Vicryl® (Ethicon UK).
Skin transplantation. Full-thickness skin transplantation was performed using a
modiﬁed technique of that originally described by Billingham et al.66. Tail skin
from donor mice was prepared immediately post-mortem, making a circumfer-
ential incision around the base of the tail and then extending the incision distally
along the ventral midline. The tail skin was then stripped, placed into cold PBS and
fashioned into three 1 × 1 cm2.
Recipient animals were placed under general anesthesia prior to shaving the
right ﬂank and preparing skin with chlorhexidine solution. The graft bed was
prepared by dissecting skin from the right ﬂank, taking care to preserve underlying
subcutaneous adipose tissue (for microvascular blood supplementary to the graft).
Optimally, the skin defect created was slightly larger than the size of the graft (1
mm at each edge), so that the graft remained taught and the risk of seroma
formation was minimised. Following placement of the graft onto the graft bed, it
was secured in place with methylated ﬂexible collodion (William Ransom & Son
Ltd.), applied sparingly along the wound edges. The grafts were covered with an
iodine-impregnated non-adherent dressing (Inadine®, Johnson and Johnson
Medical) and then secured in place with tape. Dressings were removed seven days
after skin grafting under a brief general anaesthetic; any animals that managed to
remove wound dressings before day 7 were excluded (prospectively) from the
experiment as technical failures. Allografts were monitored on a daily basis
following the removal of dressings and rejection was deﬁned as more than 90%
necrosis by surface area, or when the graft had completely left the recipient.
Assessment of graft necrosis was performed in a blinded fashion – after surgery,
graft recipients were placed into numbered cages; grafts were monitored according
to cage number and were then matched to experimental groups for analysis at the
end of each experiment.
Separately, skin grafts were harvested 7 days after transplantation and
specimens were ﬁxed in 10% buffered formalin solution overnight, then stored in
100% ethanol. Specimens were embedded in parafﬁn and then cut in 4 μm
transverse sections. Haematoxylin and eosin (H&E) staining was then performed
under automated protocol with a Gemini varistainer (Thermo Scientiﬁc), according
to the manufacturer’s instructions. Histological scoring of rejection was performed
in a blinded fashion by a consultant histopathologist. Scoring was performed on
three histological sections of each skin graft according to features of vasculitis,
folliculitis, dermal inﬂammation and epidermal degeneration, as described by
Zdichavsky et al.33 Images were captured using a Leica DFC290 compound
microscope and Leica Application Suite software.
Primary ﬁbroblast cell culture. All human samples were obtained with informed
signed consent and with research ethics committee approval (10/H0504/9, 10/
H0720/12 and 12/EM/0058). Primary human lung ﬁbroblast cell lines were gen-
erated by explant culture. Brieﬂy, 1 mm3 explants were dissected from normal
human lung tissue were cultured in Dulbecco’s modiﬁed eagle’s medium (DMEM)
containing 20% FCS (v/v), penicillin (100 U/ml), streptomycin (100 μg/ml), and
2.5 μg/ml amphotericin B. A near conﬂuent monolayer of ﬁbroblasts was obtained
after 3 to 4 weeks and passaged. Fibroblast cell line purity was conﬁrmed by
immunohistochemical characterization using antibodies to cytokeratin, von Will-
ebrand factor, and desmin to rule out contamination by epithelial, mesothelial,
endothelial, or smooth muscle cells. Experiments were conducted on cells between
passages 3 and 8.
In vitro ﬁbrosis assay. Collagen biosynthesis and myoﬁbroblast differentiation in
96 well format was measured by a high-content imaging based on a molecular
crowding assay modiﬁed from a previously described method67. Brieﬂy, conﬂuent
human lung ﬁbroblasts were cultured in DMEM containing 0.4% FCS and ascorbic
acid (100 μM), in the presence of mixed Ficoll 70 and Ficoll 400 (Sigma Aldrich) as
molecular crowding agents. Cells were stimulated with serial molar equivalent
concentrations of active TGF-β1 (R&D Systems) or Hp-TGM and incubated for 48
h. Cells were ﬁxed and stained with antibody speciﬁc for human collagen 1 (Sigma
Aldrich) or αSMA (Dako), ﬂuorescent secondary antibody (Alex Fluo488) and
nuclei counterstained with DAPI for per cell normalisation. Fluorescent signal was
quantiﬁed on the INCELL 6000 high content system. Mean ﬂuorescent intensity
per well was calculated with 4 reads per well. Data were expressed as the mean ±
SEM intensity of 4 technical replicates. EC50 values were calculated using four-
parameter non-linear regression.
Statistical analyses. All statistical analyses were performed using Prism 6.0
(Graphpad Software Inc.). For comparisons of two groups, Student’s two-tailed t-
test was used, assuming unequal variance. When three or more groups were
analysed, a one-way ANOVA test was used with Tukey’s multiple comparison test.
Graft survival curves were compared by Kaplan–Meier analysis; the statistical
signiﬁcance of difference in survival between experimental groups was determined
by a log rank chi-square test. P values of < 0.05 were considered to be signiﬁcant;
the following symbols were used to indicate signiﬁcance levels: denoting *p< 0.05,
denoting **p< 0.01, denoting ***p< 0.001 and denoting ****p< 0.0001. Sample
sizes were chosen empirically on the basis of the laboratory’s previous experience in
the calculation of experimental variability (sample sizes for each experiment were
not pre-determined by individual power calculations).
Data availability. Sequence data that support the ﬁndings of this study have been
deposited in NCBI with the primary accession code MG099712. All other data are
available from the corresponding author upon request.
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